← Back to Screener
Gelteq Limited Ordinary Shares (GELS)
Price$0.70
Favorite Metrics
Price vs S&P 500 (26W)-54.90%
Price vs S&P 500 (4W)-17.39%
Market Capitalization$5.38M
All Metrics
Book Value / Share (Quarterly)$1.06
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.93%
Cash Flow / Share (Quarterly)$-0.41
Price vs S&P 500 (YTD)-16.64%
EPS (TTM)$-0.76
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-0.76
EPS (Annual)$-0.50
ROI (Annual)-33.19%
Gross Margin (Annual)30.34%
Cash / Share (Quarterly)$0.02
ROA (Last FY)-30.94%
EBITD / Share (TTM)$-0.48
ROE (5Y Avg)-20.64%
Cash Flow / Share (Annual)$-0.41
P/B Ratio0.66x
P/B Ratio (Quarterly)1.47x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-3.62x
ROA (TTM)-42.71%
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)0.27x
Quick Ratio (Quarterly)0.14x
3-Month Avg Trading Volume0.70M
52-Week Price Return-19.92%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)63.15x
Asset Turnover (Annual)0.01x
52-Week High$4.11
EPS Excl Extra (Annual)$-0.50
26-Week Price Return-46.15%
Quick Ratio (Annual)0.14x
13-Week Price Return-39.66%
Total Debt / Equity (Annual)0.27x
Current Ratio (Quarterly)0.27x
Enterprise Value$10.276
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4011.74%
Cash / Share (Annual)$0.02
3-Month Return Std Dev115.84%
Net Income / Employee (TTM)$-1
ROE (Last FY)-42.05%
Net Interest Coverage (Annual)-4.44x
EPS Basic Excl Extra (Annual)$-0.50
Total Debt / Equity (Quarterly)0.27x
EPS Incl Extra (TTM)$-0.76
Receivables Turnover (Annual)6.11x
ROI (TTM)-46.59%
Revenue / Share (Annual)$0.01
Price vs S&P 500 (52W)-55.01%
Year-to-Date Return-12.50%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-16.14%
Net Profit Margin (Annual)-4011.74%
Month-to-Date Return5.90%
EBITD / Share (Annual)$-0.30
Operating Margin (Annual)-3015.94%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-17.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.76
P/B Ratio (Annual)1.47x
Book Value / Share (Annual)$1.06
Price vs S&P 500 (13W)-42.52%
Beta4.03x
Revenue / Share (TTM)$0.01
ROE (TTM)-57.52%
52-Week Low$0.64
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GELSGelteq Limited Ordinary Shares | — | — | — | — | $0.70 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Gelteq Ltd develops proprietary gel-based delivery systems for prescription drugs, nutraceuticals, and pet care products. The company's patent-pending technology enables multi-ingredient dosage forms while preserving the efficacy and accessibility of oral delivery. The business model combines technology licensing to manufacturers with white label production services.